Dermatology Doctors in Richland, WA Accepting Medicare

5 Dermatology doctors found. Showing 1 - 5

Robert J Marshall, M.D. Dermatology - Procedural Dermatology Medicare: Accepting Medicare Assignments Practice Location: 925 Stevens Dr, Suite 3-c, Richland, WA 99352 Phone: 509-946-0400    Fax: 509-946-1685

Dr. Sidney B Smith, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1295 Fowler St # 1b, Richland, WA 99352 Phone: 509-783-2004    Fax: 509-783-1949

Dr. Jeremy Walter Peck, M.D., PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 112 Columbia Point Dr Ste 105, Richland, WA 99352 Phone: 509-873-7140    Fax: 509-818-1303

Geoffrey Stillman Ames, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 750 Swift Blvd, 10, Richland, WA 99352 Phone: 509-943-3934    Fax: 509-943-4016

Nicole Mulkey, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 104 Columbia Point Dr, Richland, WA 99352 Phone: 509-942-3190    Fax: 509-943-6197

News Archive

ICR researchers identify how genetic variant linked to leukaemia helps cancer cells survive

Scientists at The Institute of Cancer Research, London, have identified how an inherited genetic variant, associated with an increased risk of developing the most common type of leukaemia, helps cancer cells survive. The findings could lead to new ways to target the disease.

Bristol-Myers Squibb to present on belatacept at American Transplant Congress

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 - 5 in San Diego.

Oral administration of Jakinibs reduces Parkinson's disease pathogenesis in rat model

University of Alabama at Birmingham researchers report the first documentation that suppressing a key cell-signaling pathway in a rat model of Parkinson's disease reduces pathogenesis. Oral administration of AZD1480 — one of the JAK/STAT pathway inhibitors generally known as Jakinibs — lessened the destructive inflammation and nerve cell degradation in the area of the brain affected by Parkinson's.

ITMTX treatment effective in late stages/progressive forms of MS: Study

The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology. This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease.

Read more Medical News

› Verified 8 days ago